An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Condition:   Breast Cancer, Early Breast Cancer Interventions:   Drug: Camizestrant;   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Abemaciclib Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials